Forge Biologics to Present and Participate at Upcoming Investor Conferences
Ohio Pen/10194062

COLUMBUS, Ohio--(BUSINESS WIRE)--Forge Biologics, a gene therapy-focused contract development and manufacturing organization, announced today that company leadership members will be making presentations and taking one-on-one meetings at three upcoming investor relations conferences.

Jefferies Cell & Genetic Medicine Summit
Friday, September 30, 10:00-10:25 a.m. ET
Presenter: Christina Perry, Senior Vice President and Head, Finance & Investor Relations
Webcast Link: https://wsw.com/webcast/jeff259/forge/2001825

Chardan Genetic Medicines Conference
Monday, October 3, 2:00-2:25 p.m. ET
Presenter: Timothy J. Miller, CEO, President and Co-Founder
Webcast Link: https://wsw.com/webcast/chard14/forge/2063205

More on Ohio Pen

• Lick Personal Oils Introduces the Ultimate Valentine's Day Gift Collection for Romantic, Thoughtful Gifting
• The Best IP Protection for Solo Inventors and Tinkerers Using Instant IP
• Copyright vs. Patent: What Inventors Need to Know
• Tom Quigley of ClaimLinx Warns Americans as Enhanced ACA Subsidies Officially Expire
• Lacy Hendricks Earns Prestigious MPM® Designation from NARPM®

SVB Securities Biopharma Private Company Connect
Wednesday, October 26, 2022
Company executives will hold virtual one-on-one meetings with investors during the event. Meetings with the management team may be requested through SVB Securities.

Forge's presentations will be available for 90 days following each event by visiting the Company's Events website at https://www.forgebiologics.com/news/#events.

About Forge Biologics

Forge Biologics is a hybrid gene therapy contract manufacturing and clinical-stage therapeutics development company. Forge's mission is to enable access to life changing gene therapies and help bring them from idea to reality. Forge's 200,000 square foot facility utilizes 20 cGMP suites in Columbus, Ohio, the Hearth, to serve as its headquarters. The Hearth is a custom-designed cGMP facility focused on AAV manufacturing and can host end-to-end manufacturing services to accelerate gene therapy programs from preclinical through clinical and commercial stage manufacturing. By taking a patients-first approach, Forge aims to accelerate the timelines of these transformative medicines for those who need them the most. To learn more, visit www.forgebiologics.com.

More on Ohio Pen

• Walmart $WMT and COSTCO.COM $COST Distribution as SonicShieldX™ Platform Sets the Stage for Accelerated Growth in 2026: AXIL Brands (N Y S E: AXIL)
• AI-Driven Drug Development with Publication of New Bioinformatics Whitepaper for BullFrog AI: $BFRG Strengthens Its Position in AI Drug Development
• IQSTEL Enters 2026 from a Position of Strength Following Transformational Year Marked by N A S D A Q Uplisting, Record Revenue and First-Ever
• Alternatives to Patents for Independent Inventors
• How Inventors Can Prove Idea Ownership Instantly Using Instant IP

Contacts

Media Inquiries
Marina Corleto
Senior Manager, Marketing and Communications
media@forgebiologics.com

Investor Relations
Christina Perry
Senior Vice President, Head of Finance and Investor Relations
Investors@forgebiologics.com

---

Show All News | Report Violation